Along similar lines, (p53 wild-type) lung cancer with EGFR, ALK or ROS1 mutations has an inherently better prognosis than lung cancer with TP53 mutations, as the latter are frequently associated with additional genetic alterations, chromosomal instability and aneuploidy, generating the genetic plasticity needed for a highly malignant phenotype [73,74]. The gene discussed is EGFR; the disease is lung carcinoma.